|
Louis P. Lacasse, of Montreal, Quebec, has served on the Board since December 1995. He is President of GeneChem Management Inc., an organization that manages biotechnology venture capital funds. Prior to joining GeneChem in April 1997, Mr. Lacasse was Vice-President of Healthcare and Biotechnology at SOFINOV, the venture capital subsidiary of the Caisse de dépôt et placement du Québec. During his ten years with SOFINOV and the Caisse de dépôt et placement du Québec, Mr. Lacasse was involved in numerous investments in small and medium-sized businesses in high technology industries such as biotechnology, software and telecommunications. He was also responsible for setting up a network of regional venture capital funds throughout Quebec and for investments in funds both in Canada and the United States.
Mr. Lacasse is presently a director of Methylgene Inc., Warnex Inc. and Chromos Molecular Systems Inc., three publicly traded companies and of Émérillon Thérapeutique Inc., a privately held company. He is also Chairman of the Audit Committee of the three publicly traded companies enumerated above. | 